MICRODROPLET BASED SUSTAINED DELIVERY OF NALTREXONE

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$46,575.00
Award Year:
1991
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
16814
Agency Tracking Number:
16814
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
4364 S Alston Ave, Durham, NC, 27713
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Indu Parikh
(919) 361-2286
Business Contact:
() -
Research Institution:
n/a
Abstract
MICRODROPLET TECHNOLOGY IS A NOVEL MEANS OF IMPROVING TISSUECOMPATIBILITY AND PROVIDING SUSTAINED RELEASE OF A WATER INSOLUBLE DRUG BY DISSOLVING IT INTO MICROSPHERES, (O, LU DIAMETER) OF AN OIL PHASE AND ENCAPSULATING THEM WITHA LAYER OF PHOSPHOLIPID. A RAT MODEL WILL BE USED TO TEST TTHE MICRODROPLET TECHNOLOGY-BASED SUSTAINED DELIVERY OF A NARCOTIC ANTAGONIST, NALTREXONE. NALTREXONE IS THE DRUG OF CHOICE FOR TREATMENT OF HEROIN ADDICTION BECAUSE IT IS ESSENTIALLY A PURE NARCOTIC ANTAGONIST AND DEVOID OF ANALGESIC EFFECTS. A SERIES OF MICRODROPLET FORMATIONS CONTAINING DIFFERENT CONCENTRATIONS OF NALTREXONE WILL BE PREPARED IN AT LEAST THREE TISSUE-COMPATIBLE AND FDA APPROVED SYNTHETIC OILS. THE DRUG RELEASE KINETICS OF THE NALTREXONE-CONTAINING MICRODROPLETS WILL BE TESTED IN A IN VITRO MODEL AS WELL AS BY SUBCUTANEOUS AND INTRAMUSCULAR INJECTIONS INTO RATS. A FORMULATION WHICH PROVIDES ACCEPTABLE (ZERO ORDER) RELEASE KINETICS OVER A PERIOD OF 3-4 WEEKS WILL BE IDENTIFIED FOR FURTHER DEVELOPMENT IN A PHASE II SBIR FOR ITS POTENTIAL INDICATION FOR THE TREATMENT OF HEROIN ADDICTS. MICRODROPLET TECHNOLOGY IS A NOVEL MEANS OF IMPROVING TISSUECOMPATIBILITY AND PROVIDING SUSTAINED RELEASE OF A WATER INSOLUBLE DRUG BY DISSOLVING IT INTO MICROSPHERES, (O, LU DIAMETER) OF AN OIL PHASE AND ENCAPSULATING THEM WITHA LAYER OF PHOSPHOLIPID. A RAT MODEL WILL BE USED TO TEST TTHE MICRODROPLET TECHNOLOGY-BASED SUSTAINED DELIVERY OF A NARCOTIC ANTAGONIST, NALTREXONE. NALTREXONE IS THE DRUG OF CHOICE FOR TREATMENT OF HEROIN ADDICTION BECAUSE IT IS ESSENTIALLY A PURE NARCOTIC ANTAGONIST AND DEVOID OF ANALGESIC EFFECTS. A SERIES OF MICRODROPLET FORMATIONS CONTAINING DIFFERENT CONCENTRATIONS OF NALTREXONE WILL BE PREPARED IN AT LEAST THREE TISSUE-COMPATIBLE AND FDA APPROVED SYNTHETIC OILS. THE DRUG RELEASE KINETICS OF THE NALTREXONE-CONTAINING MICRODROPLETS WILL BE TESTED IN A IN VITRO MODEL AS WELL AS BY SUBCUTANEOUS AND INTRAMUSCULAR INJECTIONS INTO RATS. A FORMULATION WHICH PROVIDES ACCEPTABLE (ZERO ORDER) RELEASE KINETICS OVER A PERIOD OF 3-4 WEEKS WILL BE IDENTIFIED FOR FURTHER DEVELOPMENT IN A PHASE II SBIR FOR ITS POTENTIAL INDICATION FOR THE TREATMENT OF HEROIN ADDICTS.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government